Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
AssigneeImmunityBio, Inc.
InventorsFerdous Anower-E-Khuda, Gene Yeh, Syed Raza Ali, Manju Saxena, Leonard Sender, Patrick Soon-Shiong
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods related to potent cytotoxic M-CENK cells from CD3/CD14 depleted apheresis products.
Claims24
A method of generating memory-like cytokine enhanced natural killer (M-CENK) cells from a blood sample, the method comprising:
- (a) removing CD3+ cells and CD14+ cells from the blood sample to obtain a CD3− CD14− population of cells;
- and
- (b) incubating the CD3− CD14− population of cells with a first cytokine composition comprising a stabilized IL-15 analog or fusion protein comprised thereof for a first period (optionally 8-10 days), and
- (c) incubating the CD3− CD14− population of cells with a second cytokine composition comprising i) IL-15 or a stabilized derivative thereof, ii) IL-18 or a stabilized derivative thereof, and iii) IL-12 or a stabilized derivative thereof for a second period (optionally 14-16 hours), thereby producing a population of CD56+ enriched M-CENK cells.
A method of treating a patient diagnosed with cancer, the method comprising:
- (a) obtaining a blood sample from the patient;
- (b) removing CD3+ cells and CD14+ cells from the blood sample to obtain a CD3− CD14− fraction;
- (c) contacting the CD3− CD14− fraction with IL-15 or a stabilized derivative thereof for a first period of time;
- (d) contacting the CD3− CD14− fraction with IL-12 or a derivative thereof, IL-18 or a derivative thereof, and IL-15 or a derivative thereof, for a second period of time, thereby obtaining a cell culture comprising a population of CD56+ enriched M-CENK cells;
- (e) centrifuging the cell culture to produce a supernatant;
- (f) isolating exosomes from the supernatant;
- and
- (g) administering the isolated exosomes to the patient, thereby treating the cancer.
A kit for preparing CD56+M-CENK cell exosomes, the kit comprising:
- i) reagents for depleting CD3+ cells and CD14+ cells from a blood sample;
- ii) IL-15 or a fusion protein comprised thereof, iii) IL-12 or a fusion protein comprised thereof, and iv) IL-18 or a fusion protein comprised thereof.
A population of CD56+ enriched M-CENK cells wherein at least 90% of the cells are CD3−, CD14−, and CD56+, and wherein at least 60% of the cells express CD16.
A cell culture mixture comprising a population of blood cells that are CD3− CD14−, a first cytokine composition comprising a stabilized IL-15 analog or fusion protein.
Dependencies are inferred from the claim text.